Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making
BackgroundThe current drug development paradigm has been criticized for being too drug-centered and for not adequately focusing on the patients who will eventually be administered the therapeutic interventions it generates. The drug-driven nature of the present framework has led to the emergence of...
Main Authors: | Robbe Saesen, Stéphane Lejeune, Gianluca Quaglio, Denis Lacombe, Isabelle Huys |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.00043/full |
Similar Items
-
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
by: Stefanie Broes, et al.
Published: (2021-01-01) -
Pharmacoepidemiology Research-Real-World Evidence for Decision Making
by: Anick Bérard, et al.
Published: (2021-09-01) -
Assessing stroke severity using electronic health record data: a machine learning approach
by: Emily Kogan, et al.
Published: (2020-01-01) -
Personalized and long-term electronic informed consent in clinical research: stakeholder views
by: Evelien De Sutter, et al.
Published: (2021-07-01) -
Stakeholder perspectives on clinical research related to therapies for rare diseases: therapeutic misconception and the value of research
by: Kylie Tingley, et al.
Published: (2021-01-01)